Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2008-05-27
2008-05-27
Bunner, Bridget (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C530S300000, C530S324000, C514S002600, C514S012200
Reexamination Certificate
active
10086177
ABSTRACT:
In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.
REFERENCES:
patent: 2530369 (1950-11-01), Simons et al.
patent: 2760992 (1956-08-01), Schoeffel et al.
patent: 4554101 (1985-11-01), Hopp
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5082670 (1992-01-01), Gage et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5401651 (1995-03-01), Walz
patent: 5563048 (1996-10-01), Honjo et al.
patent: 5756084 (1998-05-01), Honjo et al.
patent: 5807744 (1998-09-01), Berneman et al.
patent: 5856301 (1999-01-01), Craig et al.
patent: 5871723 (1999-02-01), Strieter et al.
patent: 5919776 (1999-07-01), Hagmann et al.
patent: 5962462 (1999-10-01), Mills et al.
patent: 5990163 (1999-11-01), Evans et al.
patent: 6013644 (2000-01-01), Mills et al.
patent: 6022848 (2000-02-01), Kozlov et al.
patent: 6046185 (2000-04-01), Burgoyne et al.
patent: 6124319 (2000-09-01), MacCoss et al.
patent: 6132987 (2000-10-01), Charo et al.
patent: 6133319 (2000-10-01), Widdowson
patent: 6136827 (2000-10-01), Caldwell et al.
patent: 6140349 (2000-10-01), Caldwell et al.
patent: 6166037 (2000-12-01), Budhu et al.
patent: 6204294 (2001-03-01), Bryan et al.
patent: 6356887 (2002-03-01), Berenson et al.
patent: 6515001 (2003-02-01), Saxena et al.
patent: 6613742 (2003-09-01), Huang et al.
patent: 6693134 (2004-02-01), Saxena et al.
patent: 6875738 (2005-04-01), Clark-Lewis et al.
patent: 6946445 (2005-09-01), Clark-Lewis et al.
patent: 2002/0156034 (2002-10-01), Tudan et al.
patent: 2002/0165123 (2002-11-01), Tudan et al.
patent: 2003/0004136 (2003-01-01), Saxena et al.
patent: 2003/0045550 (2003-03-01), Saxena et al.
patent: 2003/0092674 (2003-05-01), Saxena et al.
patent: 2003/0125380 (2003-07-01), Saxena et al.
patent: 2005/0059584 (2005-03-01), Merzouk et al.
patent: 2005/0164935 (2005-07-01), Clarke Lewis et al.
patent: 2005/0265969 (2005-12-01), Clarke Lewis et al.
patent: 2006/0014682 (2006-01-01), Clarke Lewis et al.
patent: WO 89/02468 (1989-03-01), None
patent: WO 89/05345 (1989-06-01), None
patent: WO 89/07136 (1989-08-01), None
patent: WO 90/06757 (1990-06-01), None
patent: WO 91/04274 (1991-04-01), None
patent: WO 92/07573 (1992-05-01), None
patent: WO 93/10234 (1993-05-01), None
patent: WO 93/13206 (1993-07-01), None
patent: WO 95/05452 (1995-02-01), None
patent: WO 95/09236 (1995-04-01), None
patent: WO 96/40772 (1996-12-01), None
patent: WO 97/28257 (1997-08-01), None
patent: WO 97/28258 (1997-08-01), None
patent: WO 98/04684 (1998-02-01), None
patent: WO 98/04698 (1998-02-01), None
patent: WO 98/09642 (1998-03-01), None
patent: WO 98/51705 (1998-11-01), None
patent: WO 99/47158 (1999-09-01), None
patent: WO 00/09152 (2000-02-01), None
patent: WO 00/66112 (2000-09-01), None
patent: WO 01/76615 (2001-10-01), None
Tudan et al. C-terminal cyclization of an SDF-1 small peptide analogue dramatically increases receptor affinity and activation of the CXCR4 receptor. J Med Chem. 45(10):2024-2031, 2002.
Perez et al. Increased plasma levels of stromal-derived factor-1 enhance human thrombopoiesis and mobilize human CFC in NOD/SCID mice. Exp Hematol 32: 300-307, 2004.
Zhong et al. Small peptide analogs to stromal derived factor-1 enhance chemotactic migration of human and mouse hematopoietic cells. Exp Hematol 32: 470-475, 2004.
Li et al. Identification of the CD8 loop as a surface functional epitope. J Biol Chem 273(26): 16442-16445, 1998.
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotech 18(1): 34-39, 2000.
Bork, A. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Res. 10: 398-400, 2000.
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics 14(6): 248-250, 1998.
Smith et al. The challenges of genome sequence annotation or “The devil is in the details”. Nature Biotech 15: 1222-1223, 1997.
Brenner, S.E. Errors in genome function. Trends in Genetics 15(4): 132-133, 1999.
Bork et al. Go hunting in sequence databases but watch out for the traps. Trends in Genetics. 12(10): 425-427, 1996.
Wells, J.A. Additivity of mutational effects in proteins. Biochemistry 29 (37): 8509-8517, 1990.
Ngo et al. Computational complexity, protein structure prediction, and the Levinthal paradox. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.
Ikebe et al. A hinge at the central helix of the regulatory light chain of myosin is critical for phosphorylation-dependent regulation of smooth muscle myosin motor activity. J Biol Chem. 273(28):17702-17707, 1998.
Nett et al. Changes to the length of the flexible linker region of the Rieske protein impair the interaction of ubiquinol with the cytochrome bc1 complex. Eur J Biochem. 267(18):5777-5782, 2000.
van Leeuwen et al. Linker length and composition influence the flexibility of Oct. 1 DNA binding. EMBO J. 15;16(8):2043-2053, 1997.
Robinson et al. Optimizing the stability of single-chain proteins by linker length and composition mutagenesis. Proc Natl Acad Sci USA. 95(11):5929-5934, 1998.
Acsadi, G. et al, (1991)Naturevol. 352, 815-818.
Aiuti, A. et al, (1997)J. Exp. Med.vol. 185-1, 111-120.
Aiuti, A. et al, (1999)Eur. J. Immunol.vol. 29, 1823-1831.
Alkhatib, G et al, (1996)Sciencevol. 272, 1955-1958.
Allen, M. et al, (2000)J. Biomolecular Screeningvol. 5 No. 2, 63-69.
Alleva, D. et al, (1998)J. Immunol.vol. 161-12, 6878-6884.
Anderlini, P. et al, (1997)Bloodvol. 90 No. 3, 903-908.
Anderson, W., et al, (2000)Sciencevol. 288, 627-629.
Arenzana-Selsdedos, F. et al, (1996)Naturevol. 383, 400.
Armentano, D., et al, (1990)Proc. Natl. Acad. Sci.vol. 87, 6141-6145.
Ausubel et al, (1995)Current Protocols in Mol. Biol. Supp.vol. 36, 9.10.1-9.14.6.
Avenarius, H. et al, (1993)Inter. J. Hematologyvol. 58, 189-196.
Baggiolini, M. (1998)Naturevol. 392, 565-568.
Baird, A. et al, (1999)Current Opinion in Immunologyvol. 11, 157-166.
Balasa, B. et al, (1997)J. Exp. Med.vol. 186, 385-391.
Baldari, J. et al (1987)EMBO Journalvol. 6 No. 1, 229-234.
Barbier, J. et al, (1997)J. Med. Chem.vol. 40 No. 9, 1373-1380.
Barbier, J. et al, (2000)Biochemistry 2000vol. 39 No. 47, 14522-14530.
Barnes, D. et al, (1998)J. Clin. Invest.vol. 101 No. 12, 2910-2919.
Berkner, K., (1988)Biotechniquesvol. 6 No. 7, 616-628.
Blease, K. et al, (2000)J. Immunol.vol. 165, 1564-1572.
Bleul, C. et al, (1996)J. Exp. Med.vol. 184, 1101-1109.
Bleul, C. et al, (1996)Naturevol. 382, 829-832.
Brandt, J. et al, (1990)J. Clin. Invest.,vol. 86, 932-941.
Brandt, J. et al, (1992)Bloodvol. 79 No. 3, 634-641.
Brandt, J. et al, (1998)J. Clin. Invest.vol. 82, 1017-1027.
Buckley, C. et al, (2000)J. Immunol.vol. 165, 3423-3429.
Burt, R., (1999)Stem Cellsvol. 17, No. 6, 366-372.
Campbell, J. et al, (1998)Sciencevol. 279, 381-383.
Carr, M. et al, (1994)Proc. Natl. Acad. Sci.vol. 91, 3652-3656.
Cashman, J. et al, (1999)Bloodvol. 94 No. 11, 3722-3729.
Cavazzana-Calvo, M. et al, (2000)Sciencevol. 288, 669-672.
Charo, I. et al, (1994)Proc. Natl. Acad. Sci.vol. 91, 2752-2756.
Choe, H. et al, (1996)Cellvol. 85, 1135-1148.
Chowdhury, J. et al, (1991)Sciencevol. 254, 1802-1805.
Clapp, W. et al, (1991)Bloodvol. 78 No. 4, 1132-1139.
Clark-Lewis, I. et al, (1994)J. Biol. Chem.vol. 269 No. 23, 16075-16081.
Cocchi, F. et al (1995)Sciencevol. 270, 1811-1815.
Combadiere, C. et al, (1995)
Arab Lakhdar
Cashman Johanne
Clark-Lewis Ian
Eaves Connie J.
Merzouk Ahmed
Boyer Brian S.
Bunner Bridget
Chemokine Therapeutics Corporation
The University of British Columbia
TIPS Group
LandOfFree
CXC chemokine receptor 4 agonist peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CXC chemokine receptor 4 agonist peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CXC chemokine receptor 4 agonist peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3914552